CD38-High Monocytes Flag Sepsis Early and Open New Treatment Door
A novel immune cell subset, CD38-high monocytes, spikes within 24 hours of sepsis onset and may serve as both a diagnostic marker and drug target.
Summary
Researchers at Zhejiang University used single-cell RNA sequencing and mass cytometry to map immune changes in sepsis patients. They discovered that monocytes expressing high levels of CD38 accumulate specifically within the first 24 hours of sepsis, distinguishing it from sterile inflammation like post-surgical stress. These CD38-high monocytes correlated with 28-day mortality in bacterial sepsis. Blocking CD38 reduced inflammation in lab models and sepsis mice. Mechanistically, the cells rely on hyperactivated glycolysis driven by HIF-1α, with the metabolite methylglyoxal feeding back to amplify CD38 expression — creating a destructive immune loop. The findings propose CD38-high monocytes as a clinically accessible biomarker and actionable therapeutic target.
Detailed Summary
Sepsis kills millions annually and remains notoriously difficult to diagnose early. Current biomarkers like procalcitonin and CRP lack specificity, and no single immune signature reliably distinguishes sepsis from other critical illness. This study set out to find a precise cellular fingerprint of sepsis at the single-cell level.
The researchers performed single-cell RNA sequencing (scRNA-seq) on peripheral blood mononuclear cells from sepsis patients, cardiac surgery patients (sterile inflammation controls), recovered sepsis patients, and healthy donors — totaling over 248,000 single-cell transcriptomes when combined with public datasets. They then validated findings using mass cytometry (CyTOF) in a cohort of 98 individuals, and conventional flow cytometry in 253 patients. Among nine monocyte subclusters identified, the C1 subcluster — defined by high CD38 expression — was dramatically expanded in sepsis patients within 24 hours of ICU admission, but not in surgical or mild infection patients.
Key results were striking: CD38-high monocytes were detectable by standard flow cytometry, making the finding clinically practical. In a cohort of 102 sepsis patients, elevated CD38-high monocyte frequency correlated with higher 28-day mortality. Anti-CD38 therapy (using daratumumab-like targeting strategies) significantly dampened inflammatory cytokine output in primary human monocytes and improved survival metrics in a cecal ligation and puncture mouse model of sepsis.
The mechanistic story was equally compelling. CD38-high monocytes showed hyperactivated glycolysis, driven by HIF-1α — a transcription factor upregulated when NAD+ is depleted by CD38's enzymatic activity. Further, the glycolytic byproduct methylglyoxal (MGO) was found to upregulate CD38 expression itself, establishing a self-amplifying loop: CD38 consumes NAD+, activating HIF-1α and glycolysis, producing MGO, which drives more CD38 — progressively worsening immune dysregulation. SCENIC transcription factor analysis identified IRF and NF-κB family regulators as key drivers of the CD38-high state.
The study's translational implications are significant. CD38 is already a validated drug target in multiple myeloma (daratumumab), meaning approved agents could potentially be repurposed for sepsis. The ability to identify CD38-high monocytes via routine flow cytometry — rather than complex sequencing — lowers the barrier to clinical implementation as a rapid diagnostic test.
Key Findings
- CD38-high monocytes accumulate specifically within 24 hours of sepsis onset, not in sterile inflammation or mild infection.
- Elevated CD38-high monocyte frequency associates with increased 28-day mortality in bacterial sepsis patients.
- Anti-CD38 targeting reduced inflammatory response in primary monocytes and improved outcomes in a mouse sepsis model.
- A CD38–HIF-1α–glycolysis–methylglyoxal positive feedback loop drives progressive immune dysregulation in sepsis.
- CD38-high monocytes are detectable by standard flow cytometry, enabling potential rapid bedside diagnostics.
Methodology
Multi-cohort study using scRNA-seq (>248,000 cells), CyTOF validation (n=98), and flow cytometry (n=253 patients including 102 sepsis cases). Mechanistic studies were conducted in primary human monocytes and a cecal ligation and puncture mouse model; transcription factor activity was assessed via SCENIC analysis.
Study Limitations
The scRNA-seq discovery cohort was small (n=3 per group), and the mechanistic mouse model may not fully replicate human sepsis heterogeneity. The study does not yet establish the diagnostic sensitivity/specificity cutoffs needed for routine clinical deployment, and causality of the MGO–CD38 loop in human patients requires further validation.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.